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Abstract: Viruses are intracellular parasites that require a permissive host cell to express the viral
genome and to produce new progeny virus particles. However, not all viral infections are productive
and some viruses can induce carcinogenesis. Irrespective of the type of infection (productive or
neoplastic), viruses hijack the host cell machinery to permit optimal viral replication or to transform
the infected cell into a tumor cell. One mechanism viruses employ to reprogram the host cell is through
interference with signaling pathways. Polyomaviruses are naked, double-stranded DNA viruses
whose genome encodes the regulatory proteins large T-antigen and small t-antigen, and structural
proteins that form the capsid. The large T-antigens and small t-antigens can interfere with several
host signaling pathways. In this case, we review the interplay between the large T-antigens and small
t-antigens with host signaling pathways and the biological consequences of these interactions.
Keywords: apoptosis; DNA damage response; immune response; interferon; MAP kinase; NFκB;
p53; PI3K; protein phosphatases; retinoblastoma
1. Introduction
The Polyomaviridae family consists of naked viruses with an icosahedral capsid structure. Although
originally isolated in mammals, polyomaviruses (PyV) also infect birds and, recently, PyV sequences
have also been detected in insects, fish, amphibians, and reptiles. However, it remains to be established
whether PyV can actually infect these species [1,2]. The circular double-stranded DNA genome of
PyV encodes regulatory and structural proteins, which are expressed in a time-dependent fashion.
The regulatory proteins are expressed before the onset of viral DNA replication and are referred to
as the early proteins, whereas the structural proteins are synthesized later in the infection cycle and,
therefore, are called the late proteins. The early proteins are required for viral DNA replication and
transcription, while the late proteins form the capsid [2].
So far, 14 different human polyomaviruses (HPyV) have been described. BKPyV and JCPyV were
the first HPyV to be isolated in 1971 and they were named after the initials of the patient [3,4]. In the
last decade, 12 novel HPyV have been described: KIPyV [5], WUPyV [6], Merkel cell polyomavirus
(MCPyV; [7]), HPyV6 [8], HPyV7 [8], Trichodysplasia spinulosa-associated polyomavirus (TSPyV; [9]),
HPyV9 [10], MWPyV [11,12], STLPyV [13], HPyV12 [14], NJPyV [15], and LIPyV [16]. They all encode
at least two early proteins: large T-antigen (LT) and small t-antigen (sT), but other early proteins have
been detected or may be encoded by the viral genome (Figure 1). Most HPyV produce three late
proteins: VP1, VP2, and VP3. BKPyV and JCPyV encode an additional non-structural late protein
known as the agnoprotein [17], whereas MCPyV does not seem to express VP3 [18]. HPyV infection is
common in the human population. Serological studies have shown a seroprevalence ranging from
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~5% for HPyV12, NJPyV, and LIPyV, ~20% for HPyV9 and ≥60% for the other HPyV in the healthy
adult population. Moreover, each individual is infected with several HPyVs [19,20]. Primary infection
occurs in early childhood, after which the virus establishes a life-long and sub-clinical co-existence
with its host [21]. Immunodeficient conditions, immunosuppressive drugs, and pregnancy can lead to
reactivation of HPyV and may cause diseases. BKPyV causes polyomavirus-associated nephropathy in
renal transplant patients and hemorrhagic cystitis in bone marrow transplants. JCPyV is associated with
progressive multifocal leukoencephalopathy and TSPyV is linked to trichodysplasia spinulosa, which
is a rare skin disease of severely immunocompromised hosts characterized by follicular distention and
keratotic spine formation [22,23]. Despite their name (poly = many and oma = cancers), MCPyV seems
to be the only HPyV to induce cancer in its natural host. MCPyV is a major cause in the skin cancer
called Merkel cell carcinoma [7,24]. The role of other HPyV, especially BKPyV and JCPyV, in human
cancer such as prostate, colorectal, urothelial, and brain cancer is disputed (for recent reviews, see
References [25–29]), but some of them can transform cells, including human cells, and the virus or
its early proteins LT or/and sT can cause tumors in animal models [27,28,30]. HPyV6 and HPyV7
may be associated with a pruritic rash [31,32], while, so far, no diseases have been associated for the
other HPyV.
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processes is by interfering with signaling pathways regulating processes such as DNA replication, 
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Viruses, including polyomaviruses, recruit the host cell machinery to favour their replication,
and, in the case of oncoviruses, to cause carcinogenesis. One way to take control or perturb cellular
processes is by interfering with signaling pathways regulating processes such as DNA replication,
the cell cycle, the immune response, transcription, metabolism, DNA repair, cell survival, cell motility,
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and angiogenesis [33–37]. In the next sections, we review the different pathways that are affected by
HPyV and discuss the biological relevance of these interactions.
2. Interaction Partners of HPyV LT and sT
One way to explore the impact of HPyV on signaling pathways is to identify which cellular
proteins can bind to LT and sT. Several methods such as co-immunoprecipitation, tandem affinity
purification coupled to mass spectrometry, GST pull down of in vitro translated proteins, stable isotope
labeling by amino acids in cell culture (SILAC)-based pull down, and yeast two-hybrid have been
used to identify cellular interaction partners of HPyV LT and sT to understand the function of these
proteins [2]. A list of cellular proteins that interact with HPyV LT and sT is given in Table 1. Some of
these proteins are part of signaling pathways and will be discussed in Section 3. A special group of
proteins that are targeted by HPyV are the protein phosphatases. Because protein phosphatases can
interfere with several signaling pathways and targeting them is one of the strategies polyomaviruses
use to optimize the host cell for their replication or to transform cells, they will be discussed in more
detail in the next paragraphs [38].
Table 1. Cellular proteins identified to interact with the early proteins of HPyV [2].
Virus LT sT T’135 T’136 T’165
BKPyV p53, pRb ABCA13, ANKRD30B, ATP2A2,
BAG2, BAG3, BAG5, cathepsin
BCCND3, CD44, CDK2,
CDKN1A, CNP, CSRP1, DnaJC7,
DP1, E2F3, E2F4, E2F5, GLIPR2,
HSDL2, Hsp70, HSPA4L,
HSPBP1, NAGK, Nse2/Mms21,
PCNA, PP2CA, PP2R1α,
PPM1B, RB1, RBL1, RBL2,
SCCPHD, SEC61B, SMC5,
SQRDL, SRP9, SRRM2,
STUB1, TGFBI
JCPyV AP1, BAG3, BRN1, β-catenin,
CEBP, Hsp70, IRS-1, LEF1, NF2,
Oct6, pRb, p53, Purα,
SKP1, YB-1
PP2Cα Hsp70, pRb pRb pRb
WUPyV p53, RB1
MCPyV ABCA13, ABCD3, AP2A1, ATM,
BAG2, BAG3, BAG5, Brd4,
CREBBP, CK2β, DDX24,
DnaJC7, DP1, E2F3, E2F4, EMD,
FAM71E2, GTF3C1, HDLBP,
Hsp70, IκBIP, KPNA2, KPNA3,
KPNA4, MAP4, MED14,
P4HA3, PGAM5, PIP4K2 β,
PP2AR1α, PTRF, RB1, RTN4,
SALL2, SDPR, SGPL1, SRP14,
SRPRB, STUB1, TCEB1, TRIM38,
TSPYL1, Vam6p, VAPA, VAPB,
VPS11, USMG5
ABHD12, ACBD3, ADAM9, AIP,
ANKRD13A, ATP2A2, BAG2,
BAG3, BAG5, cadherin 1,
CCHC, CD44, CDC20, CDH,
CNP, COPG2, DnaJA1, DnaJB4,
DnaJC7, EFEMP2, eIF4EBP1,
emerin, Fbxw7, Hsp70, IGF2R,
IκBIP, LOX, MBOAT7, MMP14,
MPZL1, MTCH2, myoferlin,
NEMO, Notch2, NSD1, P4HB,
PDGFRβ, PGRMC2, PRAF2,
PPP2CA, PPP2CB, PPP2R1A,
PP2R1B, PP4R1, PPM1A,
PPM1B, PPM1G, PSMC2,
PSMC3, PSMC4, PTTPG1IP,
Rab18, RNH1, RPL21, RPs27L,
SPARC, SQRDL, SRPRB, STUB1,
SURF4, TIMM8A, TMEM165,
TMX3, TOLLIP, USMG5,
VKORC1, YAP1
HPyV6 p53, RB1 PP2Cα, PP2R1α
HPyV7 p53, RB1
TSPyV p53, RB1 PP2Cα
MWPyV pRb PP2R1α
Int. J. Mol. Sci. 2019, 20, 3914 4 of 34
The human phosphatome consists of 264 enzymes that, depending on their substrate, include
non-protein phosphatases (e.g., phosphoinositide phosphatases), and protein phosphatases. The latter
group contains protein tyrosine phosphatases, serine/threonine phosphatases, and dual specificity
phosphatases [39]. HPyV viral proteins have been shown to interact with several serine/threonine
phosphatases and will be discussed here.
2.1. Protein Phosphatase 1 (PP1)
MCPyV sT was found to bind the catalytic subunit of PP1 [40]. The biological relevance has not
been examined, but inhibition of PP1 prevents dephosphorylation of retinoblastoma and ensures cell
cycle progression [41]. It is known that HPyV drive cells into the S phase in order to facilitate viral
genome replication [2]. This may be (partially) achieved by sT-mediated inhibition of PP1, which
results in hyperphosphorylation of retinoblastoma.
2.2. Protein Phosphatase 2A (PP2A)
PP2A is a phosphoserine/threonine phosphatase that exists as a heterotrimer composed of a
structural subunit A, a regulatory subunit B, and a catalytic C subunit [42]. Several isoforms of
each of these subunits exist, but it is mainly the B-type subunit that determines substrate specificity,
subcellular localization, and catalytic activity of the PP2A holoenzyme [43]. sT of several HPyV have
been demonstrated to interact with PP2A and this interaction is mediated by the N-terminal J domain
and the C-terminal zinc binding motif of sT [44]. BKPyV sT was originally found to interact with
~56 kD and ~32 kD cellular proteins, which were suggested to represent the scaffolding A subunit and
the catalytic C subunit of PP2A, respectively [45]. Later studies showed that BKPyV sT interacts with
PP2A Aα [46]. The biological consequences of the BKPyV sT: PP2A interaction have not been studied.
JCPyV sT can bind PP2A Aα, the C subunit, and the AC core [46–48], and sT inhibits PP2A-mediated
dephosphorylation of the agnoprotein, which is a viral protein involved in maturation and release [47].
Different studies showed the interaction between MCPyV sT and PP2A Aβ, and weakly with PP2A
Aα, but also with the catalytic subunits PP2Cα and Cβ. The binding of sT to PP2A reduced the
catalytic activity of the enzyme [40,46,49,50]. Whereas SV40 sT inhibited binding of B55α, B56α,
and B56ε, MCPyV sT excluded only B56α [40]. The biological implications of the MCPyV sT. The
PP2A interaction are not known because mutations that abrogate PP2A binding had no effect on sT’s
transforming activity [51], nor did it prevent skin hyperplasia in sT transgenic mice [52].
The effect of HPyV sT: PP2A interaction on signaling pathways was investigated for HPyV6
and TSPyV sT. Both sT were shown to bind PP2A-A and PP2A-C subunits when overexpressed
in human embryonal kidney HEK293 cells [53,54]. Wild-type, but not non-PP2A binding
HPyV6 sT induced phosphorylation and activation of mitogen-activated kinase/ERK kinase 1 and
2 (MEK1/2) - extracellular signal-regulated kinases 1 and 2 (ERK1/2)-c-Jun. The role of sT: PP2A
interaction in the life cycle of HPyV6 was not examined, nor was binding of HPyV6 sT to PP2A
monitored in HPyV6 infected host cells or tissue. TSPyV sT also activated this mitogen-activated
protein kinase (MAPK) pathway, but it was not examined whether this was PP2A-dependent [53,54].
The TSPyV middle T antigen (MT) interacted with PP2A-C and overexpression of wild-type MT, but
not a non PP2A-binding MT mutant resulted in enhanced phosphorylation of MEK1/2, ERK1/2, and
mitogen-activated protein kinase interacting protein kinase 1 (MNK1). Overexpression of MT had
no effect on the phosphorylation of other PP2A substrates such as c-Jun, 4E-BP1, pRb, AKT, SHC,
and SRC [55]. Manipulation of the MEK/ERK/MNK1 pathway by TSPyV MT may contribute to the
pathogenic properties of this virus because this pathway regulates cell proliferation, and MNK1 plays
a role in mRNA translation [56,57].
2.3. Protein Phosphatase 4 (PP4)
MCPyV sT was reported to interact with PP4 [40,49,58,59], and this interaction of MCPyV sT
and PP4C plays a role in microtubule stabilization [58]. Microtubules are essential components of
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the cytoskeleton that are important for chromosome segregation, and the control of cell shape and
polarized cell motility [60]. Stathmin is a microtubule-associated protein that, in its phosphorylated form,
stimulates microtubule assembly, while unphosphorylated stathmin destabilizes microtubules [61].
MCPyV sT was found to increase the total expression levels stathmin, but to decrease its phosphorylation
levels, and to promote microtubule destabilization and to stimulate cell motility [58]. The mechanism
by which sT increases stathmin levels is not known, but sT-mediated dephosphorylation of stathmin
depends on sT binding and interfering with PP4C’s catalytic activity. Another consequence of the
interaction between MCPyV sT and PP4 is the induction of cell motility and filopodium formation [59].
Integrin receptors play an important role in the cell motility pathway. They are αβ heterodimers that
transmit extracellular signals via mediators, including small GTPases belonging to the Rho family,
to proteins that regulate the actin cytoskeleton architecture [62]. Rho family GTPases play also a
role in tumor invasion and cancer metastasis as regulators of actin cytoskeletal dynamics [63,64].
Expression of MCPyV sT upregulated the protein levels of stathmin as previously shown [58], but also
of cofilin-1, cortactin, and actin-related protein 2/3 complex subunit, which are all involved in actin
rearrangements [59]. Ectopic expression of sT expression provoked phenotypic changes in the actin
cytoskeleton, which results in the formation of filopodia. Filopodium formation depended on the
interaction between MCPyV sT and PP4C, and sT-induced cell motility and filopodium formation
required the GTPases RhoA and cell division cycle protein 42 (Cdc42), but not Rac1. sT elicited increased
levels of GTP-bound (active) RhoA and Cdc42. sT-triggered activation of Cdc42 and RhoA seems to be
mediated by Thr788 and Thr 789 dephosphorylation of β1 integrin by PP4C [59]. In conclusion, the sT:
PP4 interaction leads to dephosphorylation of β1 integrin (and maybe other integrins), which then
contribute to the cell motility cascade through the small GTPases RhoA and Cdc42. The mechanism
by which sT upregulates expression of actin remodeling proteins remains to be determined. MCPyV
sT was also shown to stimulate cell motility by upregulating transcriptional levels of A Disintegrin
and Metalloproteinase 10 (ADAM 10) [65]. The transcription factors ACAD8, PPARG, and ITGB3BP
activate the ADAM10 promoter, and their genes are induced by MCPyV sT [66]. The sT: PP4 association
also interferes with the NFκB pathway and will be discussed in Section 3.12.1.
3. The Effect of HPyV LT and sT on Signaling Pathways
3.1. Phosphatidyl-3-kinase/AKT/Mammalian Target of Rapamycin Pathway
A central signaling cascade that regulates cellular processes such as growth, motility, survival,
metabolism, and angiogenesis is the phosphatidyl-3-kinase/AKT/mammalian target of the rapamycin
(PI3K/AKT/mTOR) pathway [67]. Perturbed activation of this pathway is observed in various human
cancers [68]. Many viruses target this pathway to ensure successful replication, but they may also
subvert this pathway to induce cancer [69]. Signaling through the PI3K/AKT/mTOR pathway occurs
through ligands that bind to membrane-bound receptor protein tyrosine kinases. This interaction
results in autophosphorylation on tyrosine residues. PI3K is then recruited to the membrane by
directly binding to these phosphotyrosines. This leads to the activation of PI3K. Activated PI3K
converts phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-triphosphate
(PIP3), which then recruits the protein serine/threonine kinase-3′-phosphoinositide-dependent kinase 1
(PDK1). PDK1 phosphorylates and activates AKT. AKT signaling promotes mTOR activity through
inhibitory phosphorylation of tuberous sclerosis complex (TSC) proteins 1/2, which act as mTOR
inhibitors. mTOR is a complex that consists of mTORC1 and mTORC2 [70,71].
Earlier studies had shown that SV40 LT, through an interaction with insulin receptor substrate
1 (IRS-1) and sT, and via inhibition of protein phosphatase 2A (PP2A) could activate the AKT
pathway [72,73]. It was, therefore, not a surprise that other HPyV could interfere with the
PI3K/AKT/mTOR pathway. Following IGF-I stimulation of a JCPyV LT expressing medulloblastoma
cell line (BsB8) and a LT-negative medulloblastoma cell line (Bs-1a), a prolonged (>3 h after stimulation)
phosphorylation of AKT was observed in the LT-positive cells, whereas a very transient (~30 min)
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phosphorylation of AKT was observed in the cells lacking LT [74]. Another study showed that stable
expression of JCPyV LT in the human colon cancer cell lines HCT116 and SW837 resulted in ~3-fold to
~5-fold increase in invasion and migration compared with empty vector transfected control cells [75].
Microarray analysis identified more than 500 genes involved in cell motility that differentially expressed
between the LT expressing HCT116 cells and the control cells. From 43 up-regulated or down-regulated
genes involved in migration and invasion, 20 were specifically associated with the AKT pathway.
Moreover, phosphorylation levels of AKT were increased in LT expressing cells compared with the
control cells and specific AKT inhibitors strongly reduced migration and invasion [75]. Hence, JCPyV
LT may promote metastasis by further stimulating the activated AKT pathway. The mechanism by
which LT triggered the AKT pathway was not investigated. It should be noted that HCT116 cells contain
an activating PIK3CAH1047R mutation [76], which leads to increased AKT activation [77]. However,
JCPyV LT further increased the phosphorylation levels, but not the total protein levels of AKT.
The presence of mutations in the PI3K encoding gene (PIK3CA gene) and AKT gene, as well as
the phosphorylation levels of AKT at Thr308 in Merkel cell carcinoma (MCC) tumor samples and cell
lines were investigated [78]. Two out of 38 MCC samples had heterozygous mutations in the PI3KCA
gene, whereas none of the eight cell lines had mutations. The most common mutation that activates
AKT, glutamine residue 17 into lysine [79,80], was not detected in any of the MCC tumors or cell
lines examined. Immunohistochemistry with phosphoAKT antibodies showed strong or very strong
staining for 90% of the samples. However, no significant correlation between phosphoThr308 AKT and
MCPyV status in MCC cell lines and MCC tumors was observed [78]. These results suggest that AKT
phosphorylation in most MCC is independent of mutations in PIK3CA and in AKT, and of the presence
of MCPyV. The latter indicates that neither LT nor sT are responsible for AKT phosphorylation in
MCC. Another study found that the mRNA levels of TSC1, TSC2, and mTOR but not the protein levels,
were significantly higher in virus-negative samples compared with virus-positive MCC tumors. AKT
phosphorylation at Thr308 was also significantly higher, whereas phosphorylation of Ser473, which is
another activation event of AKT, was not statistically significantly different between virus-negative
and virus-positive MCCs [81]. Nardi et al. measured AKT phosphorylation at Thr308 and Ser473
in two MCPyV-positive (MKL-1 and MKL-2) and four virus-negative (MCC13, MCC26, UIOS, and
MGH-mcc1) MCC cell lines. AKT phosphorylation at both sites was detected in all virus-negative cell
lines, but not in the virus-positive cell lines [82]. Taken together, these results indicate that MCPyV does
not interfere with the PI3K/AKT/mTOR pathway. This assumption was further confirmed by RNA
interference studies. Silencing LT and sT in four MCPyV positive MCC cell lines had no effect on AKT
phosphorylation [78]. Despite the high levels of phosphorylated AKT, a role for MCPyV LT and sT in
activation of PI3K or AKT in MCC seems unlikely. However, the strong phosphorylation/activation
of the AKT cascade in the majority of screened MCC makes this pathway an attractive therapeutic
target. The PI3K inhibitor LY294002 abrogated AKT phosphorylation and induced cell cycle arrest
and apoptosis in MCC cells [78]. Similarly, rapamycin, which is an mTOR inhibitor, had little effect
on MCC cell line survival or proliferation [51]. Whether sT of other HPyV can interfere with the
PI3K/AKT/mTOR pathway has not been investigated.
A well–known substrate of the PI3K/AKT/mTORC1 pathway is the eukaryotic initiation factor
4E-binding protein 1 (4E-BP1). 4E-BP1 belongs to a family that contains 4E-BP1, -2, and -3 and exists in
one unphosphorylated (4E-BP1α) and three phosphorylated isoforms (β, γ, and δ) with increasing
degrees of phosphorylation [83]. In its unphosphorylated or hypo-phosphorylated form, 4E-BP1 binds
eukaryotic initiation factor 4E (eIF4E). This interaction prevents assembly of eIF4F onto capped mRNA
and, therefore, inhibits cap-dependent translation. In its phosphorylated form, 4E-BP1 dissociates from
eIF4E, which, thereby, allows cap-dependent translation. Phosphorylation of human 4E-BP1 can occur
at serine residues 65, 83, and 101 and threonine residues 37, 46, and 70, and is mediated by multiple
protein kinases [83,84]. 4E-BP1 has been shown to play an important role in cancer [83,84]. Expression of
MCPyV LT in HT1080 cells did not promote 4E-BP1 phosphorylation [85], whereas MCPyV and HPyV7
sT enhanced phosphorylation of 4E-BP1δ and, to a lesser extent, 4E-BP1γ at Ser-65. TSPyV and HPyV6
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sT had no effect on 4E-BP1 phosphorylation [51,86]. MCPyV sT had no effect on phosphorylation of
Thr37, Thr46, and Thr70 [51]. The phosphorylation of these residues by HPyV6, HPyV7, and TSPyV
was not investigated [86]. Studies with wild-type and non-PP2A binding MCPyV sT mutants revealed
that PP2A was not required for sT-induced 4E-BP1 phosphorylation and was independent of mTOR
kinase activity [51]. In a later study by the same group, it was shown that MCPyV sT can provoke
phosphorylation of all three threonine residues of 4E-BP1. The authors demonstrated that sT bound to
Cdc20 and possibly to the Cdc20 homolog 1 (Cdh1). This activated the CDK1/cyclin B1 complex and
CDK1, which resulted in phosphorylation of 4E-BP1 at all sites (Ser83 was not investigated) [87,88].
4E-BP1 hyperphosphorylation, including at Ser83, was required for MCPyV sT-induced transformation
of rodent cells [51,88]. The biological relevance of sT-mediated 4E-BP1 phosphorylation in MCPyV’s
lifecyle or MCPyV-induced MCC is not completely understood, but sT-induced hyperphosphorylation
of 4E-BP1 can lead to cap-dependent translation, which may contribute to MCPyV’s role in MCC
because dysregulated cap-dependent translation promotes tumorigenesis [89]. However, pSer65
4E-BP1 was detected in both virus-negative and virus-positive MCCs. The phosphorylation levels
were not quantified, nor was phosphorylation at other phospho-acceptor sites investigated.
3.2. Wnt Signalling
The Wnt signaling cascade is a major pathway in cells and aberrant expression is tightly
associated with cancer [90]. The Wnt signal transduction pathway can occur in a β-catenin-dependent
and β–independent manner. The β-catenin-dependent or canonical pathway depends on the
phosphorylation state of β-catenin. β-catenin is part of a multiprotein complex that contains the
scaffold protein Axin, the protein kinases glycogen synthase kinase-3 α (GSK3α), and casein kinase
1α (CK1α), as well as the adenomatous polyposis coli (APC) protein. In the absence of a ligand for
the Wnt receptor, β-catenin becomes phosphorylated and ubiquitinated and is prone to proteasomal
degradation. The Wnt ligand will bind to the Wnt receptor, which is a family known as Frizzled,
and its co-receptor low-density lipoprotein receptor-related proteins (LRPs). LRP then becomes
phosphorylated by GSK3α and CK1α, which leads to recruiting a disheveled protein (Dvl). Dvl
prevents degradation of β-catenin, which leads to accumulation and nuclear translocation. Nuclear
β-catenin forms a complex with the transcription activators lymphoid enhancer factor (LEF) and T-cell
factor (TCF) and replaces transcription repressors by co-activators such as histone acetyl transferases.
This leads to transcription activation of β-catenin target genes [90].
It was demonstrated that JCPyV LT can stimulate transcription of β-catenin target genes and
can interact with β-catenin and co-localize in the nuclei [91–93]. Transient transfection studies with
a luciferase reporter plasmid demonstrated that LT and β-catenin alone increased c-Myc and cyclin
D1 promoter activities, while co-expression of LT and β-catenin resulted in a strong synergistic
effect [91,93]. In addition, genes encoding cell cycle regulatory proteins and other β-catenin responsive
genes (https://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes) including genes encoding
proteins involved in migration and invasion (e.g., matrix metalloproteinase 7 and Rac1, see below),
anti-apoptosis (e.g., survivin), and angiogenesis (e.g., vascular endothelial growth factor) were
upregulated by LT. The mechanism by which LT interferes with the β-catenin cascade is not known,
but LT may stabilize β-catenin. LT increases β-catenin levels by inhibiting its proteasomal degradation.
However, this LT-mediated stabilization of β-catenin is independent of GSK3α [94]. The authors found
that, in the presence of LT, β-catenin associates with the cell surface in a Rac1-dependent manner and
this resulted in stabilization ofβ-catenin and activation of Rac1. Alternatively, LT may stimulate nuclear
translocation of β-catenin, which is supported by the observation that nuclear localization of β-catenin
is more frequent in LT-positive colon cancers compared with LT-negative tumors [93]. Furthermore, LT
may retain β-catenin in the nucleus, or a combination of the above-mentioned mechanisms can be
imagined. It is clear that JCPyV LT’s ability to interfere with β-catenin contributes to the oncogenic
potential of this virus.
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3.3. Protein Kinase C Pathway (PKC)
Protein kinase C (PKC) is a family of serine/threonine kinases that consists of the members α, βI,
βII, γ, δ, ε, η, θ, ζ and ι [95]. Perturbed activity of PKC has been implicated in non-malignant diseases
and cancer [95–97]. PKCε plays critical roles in cancer development [98], and expression of activated
PKCε (serine 729 phosphorylated PKCε) was examined in 11 MCC specimens [99]. Eight of them
stained positive with MCPyV LT antibodies and seven of them were also positive for phospho-PKCε.
Of the three MCPyV negative MCC samples, only one expressed phospho-PKCε. These results suggest
a correlation between PKCε activation and MCPyV positivity in MCC. However, relative few samples
were examined and the involvement of MCPyV in PKCε activation remains to be proven. PKCιwas
upregulated in JCV-infected primary human fetal glial cells [100]. SV40 sT was shown to stimulate
PKCλ and PKCζ in a PP2A-dependent manner [101,102]. Whether MCPyV and JCPyV sT operate in a
similar manner to activate PKC remains to be established nor is the biological importance in the life
cycle of these viruses known.
3.4. The Mitogen-Activated Protein Kinase (MAPK) Pathways
The MAPK pathways are involved in processes controlling gene expression, cell division, cell
survival, cell death, metabolism, differentiation, and motility. The conventional MAPK pathways consist
of a cascade of three consecutive phosphorylation events executed by a MAPK kinase kinase, a MAPK
kinase, and a MAPK. There are four different subfamilies of MAPK: extracellular-regulated kinases
1/2 (ERK1/2), c-Jun N-terminal kinases (JNK), p38 MAPK, and big MAPK. The atypical MAPK are not
organized in the classical three tier cascade, and include ERK3/4, ERK7/8, and Nemo-like kinase [103].
Infection studies with JCPyV in the human glial cell line SVG-A demonstrated rapid activation
of ERK1/2. Increased ERK1/2 phosphorylation could be observed 15 minutes after infection and
was sustained for at least 6 hours. At 9 hours post infection, ERK1/2 phosphorylation returned
to baseline levels [104–106]. Inhibition of ERK1/2 reduced infection of SVG-A cells, but did
not affect viral attachment, viral entry, or trafficking, and reduced the early and late promoter
activities [105]. The mechanism of JCPyV-induced ERK1/2 activation is not known, but the rapid
enhanced phosphorylation of ERK1/2 is consistent with viral attachment and entry events [107] and
indicates that ERK1/2 activation occurs prior to expression of LT and sT. Results from another study
suggest a negative role of LT on ERK1/2 activation. IGF-I induced ERK1/2 phosphorylation lasted for
>1 hour in the LT-negative medullablastoma Bs-1a cell line cells, but ERK1/2 activation subsided after
10 minutes in the LT-positive BsB8 cells [74]. The inhibitory effect of LT may be mediated by LT-induced
AKT activation (see 2.1). Activated AKT, in turn, can phosphorylate the MAPK kinase kinase RAF,
which leads to the inhibition of the ERK1/2 pathway [108]. Activation of the MAPK ERK1/2 pathway
by HPyV may be virus-specific and/or cell-specific because BKPyV did not induce ERK1/2 activation in
the human embryonic lung fibroblast cell line HEL-299 and in Vero cells [109].
HPyV may also interfere with other MAPK pathways. One of the substrates of JNK is c-Jun, which
is a transcription factor that is part of the dimeric activating protein 1 (AP-1) complex [110]. AP-1
consists of homo-dimeric and heterodimeric complexes of the members c-Jun, JunB, and JunD of the
Jun family and c-Fos, FosB, Fra-1, and Fra-2 of the Fos family [111]. JCPyV LT associates with c-Jun and
c-Fos and prevents their interaction with the AP-1 DNA binding motif [112]. On the other hand, c-Jun,
as well as c-Fos, repressed LT-mediated activation of JCPyV DNA replication and transcription of the
late promoter. The functional consequences of the AP-1-LT interaction are not known. For the virus
life cycle, it could be a mechanism to favour early viral gene expression because: (i) similar to murine
polyomavirus, AP-1 expression was upregulated upon JCPyV infection [113], (ii) AP-1 stimulates
transcription from the JCPyV early promoter [114], and (iii) LT usurps AP-1, which prevents viral
replication and late gene expression [112]. Moreover, inhibition of AP-1 responsive genes by LT may
prevent production of pro-inflammatory cytokines, such as the tumour necrosis factor α (TNF-α), and
contribute to immune evasion [115].
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The interaction between MCPyV and MAPK pathways has not been intensively studied. Transcript
and protein levels of RAF were significantly (p = 0.04) higher in MCPyV-positive non-small cell lung
cancer samples (n = 6) compared with MCPyV-negative non-small cell lung cancer samples (n = 10)
and an adjacent benign tissue. Moreover, phosphoSer-445 BRAF levels were also significantly higher in
the virus-positive specimens than in virus-negative tumours [116]. A larger cohort must be examined
and the exact mechanism of MCPyV-induced BRAF expression and phosphorylation must be solved to
incontestably establish a role of MCPyV in the activation of the MAPK pathway.
3.5. Notch Signaling Pathway
The Notch signaling pathway mediates cell-cell communication because Notch ligands are
membrane bound and will interact with the Notch receptors, which are transmembrane proteins.
There are four human Notch receptors (Notch1–4), while there are several groups of ligands, including
Jagged 1 and 2, and Delta-like proteins. Binding of the ligand to the Notch receptor results in
conformational change that exposes Notch to a proteolytic cleavage to release the Notch intracellular
domain (NICD). NICD enters the nucleus and will bind to and displace the transcriptional receptor
CSL (CBF1/RBPjκ/Su(H)/Lag-1), which results in transcriptional activation of target genes [117,118].
Manipulation of the Notch pathway seems to be a common mechanism used by viruses in
carcinogenesis [119]. BKPyV infection of primary human mesothelial cells resulted in increased
levels of Notch1, but the biological relevance was not examined [120]. A possible role of the Notch
pathway in MCC was investigated by monitoring the levels of Notch1, Notch2, Notch3, and Jagged 1
in MCPyV-negative and positive tumours. Notch3 expression was increased in virus-positive tumours
compared to virus-negative ones, while the opposite was found for Jagged 1 [121]. Whether MCPyV
proteins are implicated in the upregulation of Notch3 and downregulation of Jagged 1 remains to be
investigated. Using tandem affinity purification/mass spectrometry, MCPyV sT, and protein(s) encoded
by the early regions of HPyV6 and HPyV7 were shown to interact with Notch2, but the functional
consequences of these interactions were not addressed [122].
3.6. Hedgehog Signaling
The hedgehog signaling pathway owes its name to the polypeptide ligand, because fruit flies
lacking the gene encoding this protein had a phenotype that resembled hedgehogs. In humans, there
are three hedgehog ligands: sonic (SHH), Indian (IHH), and desert (DHH) hedgehog. The Patched
1 (PTCH1) receptor forms a heterodimeric complex with the transmembrane protein Smoothened
(Smo). In the absence of HH, PTCH1 suppresses Smo by preventing its localization to the cell surface.
Binding of HH to the receptor releases this inhibition and allows translocation of Smo to the cell
surface. This triggers a signaling cascade resulting in the activation of the DNA binding proteins
Gli-1, Gli-2, and Gli-3. In the presence of HH, Gli-1 acts as a transcriptional activator, while Gli-3
is a transcriptional repressor. Depending on the post-translational modifications, Gli-2 can act as a
repressor or an activator [123,124]. Expression of SHH and IHH was significantly higher (p < 0.001 and
p = 0.05, respectively) in MCPyV-positive MCCs (n = 29) than in MCPyV-negative MCCs (n = 21) [125].
Brunner et al. also described higher expression of SHH, IHH, PTCH1, Smo, Gli-1, Gli-2, and Gli-3
in MCC compared to healthy skin and healthy oral mucosa [126]. However, the authors provided
no information on the MCPyV status of their MCC samples. The mechanism by which MCPyV may
upregulate the HH signaling pathway remains unknown, but virus-induced activating mutations in
components of this pathway seem unlikely since mutation analysis showed one silent point mutation
in the SHH-1B gene and one silent point mutation in exon 5 of the GLI1 gene in 14 samples [125].
MCPyV-induced activation of the HH pathway may be indirect because of the PI3K/AKT pathway,
which can also activate the HH pathway [127].
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3.7. DNA Damage Response Pathways
DNA damage repair (DDR) pathways will delay or arrest cell cycle progression in cells with damaged
DNA. This pathway is controlled by the kinases ataxia telangiectasia mutated (ATM), ATM-related and
Rad3-related (ATR), and DNA-dependent protein kinase (DNA-PK) [128,129]. ATM responds primarily
to dsDNA breaks, whereas ATR is activated by ssDNA breaks and protects the integrity of replicating
chromosomes [130]. Ds breaks trigger autophosphorylation of ATM, which results in the activation of this
kinase. Activated ATM phosphorylates Chk2, which subsequently phosphorylates downstream targets,
including p53 and H2AX (the phosphorylated form of H2AX is referred to as γ−H2AX). Activation of
ATR leads to phosphorylation of Chk1, which, in turn, can phosphorylate several substrates, including
p53 and H2AX [128,129]. Phosphorylated p53 triggers expression of p53-responsive genes whose gene
products can cause cell cycle arrest, senescence, or apoptosis [131].
Several studies have shown induction of the DDR pathway by JCPyV. JCPyV infection, LT, or
sT expression in primary human astrocytes, human neuroblastoma IMR-32, human lung carcinoma
H1299 cells, and human glial cell line SVG-A caused genomic instability and DNA damage as shown
by aneuploidy/hyperploidy of infected cells, and inhibited nucleotide excision repair (NER) activity.
Furthermore, increased phosphorylation of H2AX at Ser-139 (i.e., γ-H2AX) and the ATM and ATR
substrates Cdc2, Chk1, Chk2, replication protein A32, and p53 was measured. Elevated levels of DNA
repair proteins, including RAD51, p53, Ku70, and phosphorylated Artemis were observed [132–135].
In addition, BKPyV has been shown to induce the DDR pathway. BKPyV infection of primary human
renal proximal tubule epithelial (RPTE) cells resulted in the upregulation of several genes whose
products are implicated in the DDR, activation of ATM and ATR, and augmented phosphorylation of
their substrates [136–138]. Depletion of ATM and/or ATR resulted in decreased viral DNA replication
and viral production. In contrast, knockdown of DNA-PK gave ~2-fold increase in viral DNA and
viral titer. BKPyV was still able to induce phosphorylation of H2AX in ATM/ATR/DNA-PK triple
knockdown cells, which suggests that additional kinases may be involved in the activation of DDR
upon BKPyV infection. However, Verhagen and co-workers showed that BKPyV or LT alone were
not sufficient to activate ATM and ATR in RPTE cells [139]. The reason for this discrepancy is not
known. The ability of JCPyV to induce the DDR pathway may be cell-specific because RAD51 and
Ku70 levels were comparable in JCPyV LT negative and LT positive mouse medulloblastoma cell
lines [140]. The mechanisms by which JCPyV and BKPyV LT triggers the ATM/ATR DDR pathway
and induce chromosome instability are not known, but SV40 LT induced ATM and ATR and this was
dependent on the interaction of LT with the mitotic spindle checkpoint kinase Bub1 [141]. The sequence
of the LT required for the interaction with Bub1 is conserved in BKPyV and JCPyV LT [141], so that the
same mechanism may be operational. Additional mechanisms include LT-mediated upregulation or
repression of proteins of the DDR pathway, e.g., JCPyV LT trans-activates the RAD51 promoter [142],
whereas sT reduced expression of xeroderma pigmentosum group D protein, which is a protein
involved in NER [134]. BKPyV sT interacts with NSe2/Mms21 SUMO ligase, Nse4A, Smc5, and
Smc6, a protein complex, which is required for DNA repair [143], but the functional implication
remains to be established [122]. JCPyV and BKPyV-induced phosphorylation of DDR proteins may be
through sT-mediated inhibition of PP2A. Huang et al. reported that that relatively high concentrations
(50–100 µM) of okadaic acid, a PP2A inhibitor, also suppressed NER activity [134]. However, these
concentrations of okadaic acid will also inhibit PP1, PP2B, PP4, and PP5 [144], so that the involvement
of PP2A in inhibiting NER activity remains to be confirmed. Moreover, the non-PP2A binding sTP99A
mutant had no effect on NER activity, which indicates that JCPyV sT can induce chromosome instability
in a PP2A-independent manner [134]. Nevertheless, a role for sT-mediated inhibition of PP2A in DNA
repair is plausible because it has been demonstrated that dephosphorylation of γ-H2AX by PP2A
facilitates DNA repair [145].
Elegant work by the group of Reiss has unveiled the mechanism by which JCPyV LT affects
RAD51. They showed that JCPyV LT perturbs homologous DNA repair by interfering with the
IGF-1/IGF-IR/insulin receptor substrate 1 (IRS-1) signaling axis and this requires RAD51. The receptor
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of insulin-like growth factor I (IGF-IR) is a receptor tyrosine kinase that becomes activated by the
insulin-like growth factor 1 (IGF-1) and IGF-2. Besides its role in metabolism, this signal transduction
pathway is also involved in normal cell growth, DNA repair, regulation of cell-cell adhesion, and cell
survival. Compromised activity of the IGF-IR signaling pathway is implicated in cancer [146–148].
Normally, hypophosphorylated IRS-1 interacts with Rad51 in the cytoplasm. Upon phosphorylation
of IRS-1, Rad51 dissociates, binds BRCA-2, translocates to the nucleus, and gets engaged in DNA
repair [149]. JCPyV LT was shown to bind IRS-1 and to induce translocation of cytosolic IRS-1 to
the nucleus [150] where it usurps Rad51, which interferes with Rad51′s role in DNA repair [140].
As a result, JCPyV LT reduces the fidelity of DNA repair [140]. IRS-1 contains putative nuclear
localization signals [151] so that binding of JCPyV LT does not seem to be required for nuclear import
of IRS-1. However, LT may stimulate shuttling of IRS-1 to the nucleus and help to retain it within the
nuclear compartment.
The effect of MCPyV on the DDR pathway has also been studied. Infection of osteosarcoma U2OS
cells with MCPyV induced the DDR pathway, as shown by enhanced phosphorylation of ATM/Chk1
and ATR/Chk2 [152]. Expression of MCPyV LT in U2OS or cervical carcinoma C33A cells caused DNA
damage and elicited phosphorylation of ATM, Chk1 (but not Chk2), H2AX, and p53, and upregulated
expression of the p53 target p21Cip1/Waf1 [152,153]. The C-terminal region of LT was required for
phosphorylation of Chk1 and p53, upregulation of p21Cip1/Waf1, and DNA damage. In accordance with
elevate p21 levels, cell cycle arrest and inhibition of cell proliferation were observed in LT expressing
cells. Full-length LT, but not C-truncated LT, which is typically found in MCPyV positive Merkel cell
carcinoma (MCC) tumours, induced the ATR/Chk1/p53 pathway. Full-length had a decreased potential
to stimulate cell proliferation and anchorage-independent cell growth compared to truncated LT. These
observations may explain why LT is C-terminally truncated in MCC. The authors also showed that
MCPyV sT or 57kT failed to increase phosphorylation of Chk1 and Chk2. In another study, the same
group showed that MCPyV utilizes host DDR factors for replication of its genome [153]. Additionally,
ATM can phosphorylate MCPyV LT at Ser-816. The non-phosphorylatable LT mutant S816A showed
reduced growth inhibiting properties and induced less apoptosis compared with wild-type LT [154].
Hence, LT-induced ATM activation may lead to ATM-mediated LT phosphorylation, which affects the
functions of LT.
3.8. Retinoblastoma-E2F Pathway
The retinoblastoma family or pocket proteins is a family of tumour suppressors that consist of
the three members pRb (RB1), p107, and p130 (RB2). They have a pivotal role in controlling cell cycle
progression from the G1 to the S phase. During the G1 to the S phase transition, RB1 is converted
from its hypophosphorylated form to its hyperphosphorylated form, while p107 and p130 become
hyperphosphorylated during the late G1 to S phase [155–157]. The retinoblastoma proteins control the
S phase cell cycle progression by regulating the transcription of E2F-responsive genes [158]. E2F is
a family of transcription factors that consists of eight known members (E2F1–8). RB1 preferentially
interacts with the activators E2F-1, E2F-2, and E2F-3a, whereas all RB members can bind the repressors
E2F-3b, E2F-4, and E2F-5 [159]. E2F-7a, E2F-7b, and E2F8 also act as repressors but do not seem to bind
retinoblastoma proteins [160]. Hypophosphorylated RB1 can repress transcription by direct binding
to the activation domain of E2F, which prevents the assembly of the transcriptional pre-initiation
complex and by recruiting histone deacetylases [161,162]. Inactivation of retinoblastoma proteins by
viral proteins is a common and major mechanism employed by all known human tumour viruses
to induce carcinogenesis [163]. It is, therefore, not unexpected that HPyV uses the same strategy.
Moreover, inhibition of the pocket proteins will drive the cells into the S phase to facilitate replication
of the viral genome.
The LT of BKPyV, JCPyV, WUPyV, MCPyV, and HPyV7 have been shown to interact with the
pocket proteins [122,164–170]. Moreover, BKPyV sT, JCPyV sT, T’165, T’136, and T’135. MCPyV
truncated LT and the 57kT variant can also bind retinoblastoma proteins [122,167,168]. However,
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these HPyV early proteins do not interact with all retinoblastoma family members and they bind with
different affinity. BKPyV sT did not bind p107 [122], but was shown to interact with Cdk2 [122], which
is a kinase that can phosphorylate pRb [171]. The functional consequences of the BKPyV sT: Cdk2
interaction were not explored. JCPyV LT and the three T’ variants exhibited the highest affinity for p107
and lowest for pRb, whereas sT only binds p107 and p130 [48,170]. The interaction between BKPyV LT
and pRb was very weak and estimated to be ~50x weaker than between SV40 LT and pRb [166]. MCPyV
truncated LT interacted strongly with RB1, whereas full length LT bound weakly [170]. MCPyV LT did
not interact with the p107 and p130 members of the retinoblastoma family, nor did it interfere with
p107-induced and p130-induced cell cycle arrest and repression of E2F responsive genes [169,170,172].
A direct interaction between the sT of MCPyV and TSPyV and the pocket proteins has not
been demonstrated, but induced expression of TSPyV sT, but not MCPyV sT, which enhanced
phosphorylation of pRb in HEK293 cells [173]. Hence, TSPyV sT may play a role in trichodysplasia
spinulosa, which is a proliferative cutaneous disease [174]. pRb is a genuine substrate for PP2A [175],
so the difference in TSPyV sT and MCPyV sT to induce hyperphosphorylation of pRb may result from
their differences in binding and inactivating PP2A isoforms. The PP2A B55α subunit modulates the
phosphorylation status of pRb [176] and this subunit was not excluded by MCPyV sT (see Section 2.2).
Kazem and co-workers showed that phosphorylated pRb expression in TSPyV LT positive hair follicles
was increased when compared to healthy hair follicles from the same patients [177]. Whether LT from
this virus interacts with pocket proteins was not investigated.
The biological consequences of the interaction with the pocket proteins was not always investigated.
The interaction of JCPyV LT and the three T’ variants inhibited phosphorylation of the pocket proteins
and promoted their degradation, whereas association of sT with p107/p130 drove the cells into the
S phase and promoted replication of the viral genome [48,178]. BKPyV LT reduced the total levels
and the phosphorylation status of all three pocket proteins and increased the amount of free and
transcriptionally active e2F detected in kidney fibroblast BSC-1 cells stably expressing LT compared
to control cells or cells expressing non-pRb-binding LT mutants [166,179]. McCabe et al. showed
that BKPyV LT stimulated the promoter of the DNA methyltransferease 1 (DNMT1) gene and this
activation depends on the E2F binding sites in the promoter and on LT’s ability to interact with
the pocket proteins [180]. Infection of RPTE cells and primary human prostate epithelial cells with
BKPyV resulted in elevated DNMT1 protein levels, which coincided with LT expression. Expression of
proliferating cell nuclear antigen (PCNA), cyclin E along with E2F1 and other E2F target genes, was
also upregulated and correlated with LT expression [180,181]. Thus, LT may use the pRb: E2F pathway
to trigger expression of E2F target genes and this may contribute to virally induce transformation and
tumorigenesis. The correlation between DNM1 expression and DNA methylation in BKPyV positive
tumours has not been examined, but a significant correlation between JCPyV infection increased
DNMT1 expression, and DNA hypermethylation has been found in tumours [182–184]. However, not
all studies have confirmed a correlation between the presence of JCPyV and methylation (of specific
genes) in cancer [185]. MCPyV full-length and truncated LT were able to relieve repression by RB1 of
E2F-responsive promoters, but truncated LT was a stronger inducer of E2F-dependent transcription
than full-length LT [170]. The biological implications of WUPyV and HPyV LT interaction with the
pocket proteins was not investigated. In conclusion, targeting the Rb-E2F pathway may be a common
mechanism used by HPyV to stimulate cells entering the S phase, which favours viral replication or
may contribute to HPyV-induced tumorigenesis.
3.9. p53 Pathway
The tumour suppressor p53 is a transcription factor that binds as a tetramer to DNA in a
sequence-specific manner and activates or represses the expression of several hundred target genes [186].
p53 is a key regulator in cell cycle control, DNA repair, cell survival, senescence, autophagy, and
angiogenesis [187–189]. Mutations in the TP53 gene are observed in most cancers [190]. Furthermore,
inactivation of p53 is a common mechanism in a virus-induced cancer [163]. It is, therefore, no surprise
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that viral proteins of the HPyV also interact with p53. LT of BKPyV and JCPyV, and the LT’ variants
were shown to bind p53 [166,179,191–193]. The interaction of BKPyV LT with p53 inhibited p53 and the
p53-mediated response to DNA damage. The BKPyV promoter contains p53 binding sites and p53 was
shown to repress early promoter activity. Usurping p53 by LT alleviated the inhibitory effect of p53 on the
BKPyV promoter [194]. BKPyV-infection of RPTE cells upregulated p53 and downregulated MDM2. An
E3 ubiquitin ligase was involved in proteasomal degradation of p53. LT alone was sufficient to reduce
MDM2 levels and kept p53 inactive by binding to it [195,196]. p53 repressed JCPyV DNA replication by
interacting with LT [192]. Interaction between p53 and the LT of WUPyV was also described. However,
the effect of this interaction on viral replication or functions of p53 was not examined [122].
The C-terminal truncated LT that is expressed in MCPyV-positive MCCs lacks the conserved
p53-binding domain present in LT of other HPyV and, hence, cannot bind p53 [169]. Surprisingly,
full-length MCPyV LT failed to bind p53 as shown by co-immunoprecipitation studies in the human
osteosarcoma U2OS cells containing wild-type p53 [197] and transfected with a MCPyV LT expression
plasmid [169]. For this study, tagged-LT was precipitated with an antibody against the tag, and then
blotted with anti-p53 antibodies for the presence of p53. No reciprocal immunoprecipitation was
performed. In another study, Borchert and co-workers ectopically expressed full-length or truncated
LT and p53 in wild-type p53 expressing human embryonic kidney cells HEK293 (wild-type p53)
and in the p53 null H1299 non-small lung cancer cells [198], and showed that an antibody against
p53 could immuno-precipitate full-length, but not truncated LT [170]. However, Forster resonance
energy transfer (FRET) studies indicated that LT did not bind p53 directly. LT, but not truncated LT
inhibited p53-mediated transcription, indicated that full-length but not truncated LT may interact with
a bridging protein that serves as a co-activator in p53-driven transcription. A multimeric complex of
MCPyV LT and p53 resembles the situation with the human papillomavirus E6 protein, which forms a
complex with E6AP and p53, where neither E6 nor E6AP are separately able to recruit p53, but E6AP
renders the conformation of E6 competent for interaction with p53 [199]. A recent study reported
that the ectopic expression of C-terminal truncated MCPyV LT in IMR90 lung fibroblasts significantly
stimulated transcript levels of p53-responsive genes and increased total protein levels as well as the
Ser-15 phosphorylation levels of p53 in a pRb-binding dependent manner, whereas co-expression
with MCPyV sT. However, this thwarted the effect of truncated LT [200]. Why there are discrepancies
between the findings of Martinez-Zapien et al. and Park et al. is not clear, but the effect of MCPyV LT on
p53-mediated transcription may be cell-type specific. The inhibitory effect of MCPyV sT on p53 activity
may be explained by sT’s ability to bind and activate the transcription factor MYCL and the histone
acetylase complex EP40, and, thus, stimulate MYCL-dependent and EP400-dependent transcription.
The sT-MYCL-EP400 complex can transcriptionally regulate the expression of MDM2 and casein kinase
1α (CK1α), which is an activator of MDM4. Both MDM2 and MDM4 induce degradation of p53 [201].
The sT-MYCL/EP400-MDM2/4 connection that represses p53-driven transcription may contribute to
the role of sT in tumorigenesis of MCC.
3.10. Apoptotic Pathways
Programmed cell death or apoptosis plays an important role in development, aging, tissue
homeostasis, and in the defense mechanisms against DNA damage and infections. Failure of
apoptosis results in pathological conditions, including developmental defects, autoimmune diseases,
neurodegeneration, and cancer [202,203]. Viruses also modulate apoptotic pathways to their advantage
to ensure survival of the host cell so that they can complete viral replication, or in the case of tumour
viruses to evade apoptosis, which is one of the hallmarks of cancer [204].
HPyV can also interfere with apoptosis. One major mechanism is by neutralizing p53, which
is a protein that is central in apoptosis and regulates transcription of numerous genes involved in
apoptosis [205]. The interaction between HPyV early proteins and p53 was discussed in Section 3.9.
One of the additional targets in the apoptotic pathways targeted by HPyV are the Bcl-2 associated
athano-gene proteins (BAG). BAG is a family of co-chaperones that interact with the ATPase domain
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of heat shock protein 70. Six human BAG proteins (BAG1–6) have been described and they perform
a diversity of cellular functions, including apoptosis, differentiation, stress response, proteasomal
degradation and autophagy, and cell cycling [206]. Infection of primary human foetal astrocytes
with JCPyV resulted in the downregulation of BAG3 expression, whereas ectopic expression of LT
in U-87 MG cells reduced BAG3 levels [207]. The authors showed that LT-mediated inhibition of
BAG3 requires an AP-2 binding site in the promoter of the BAG3 gene. JCPyV LT may compete with
AP-2 for the same site because the JCPyV LT binding motif 5′-GRGGC-3′ (R = A or G) and the AP-2
consensus site 5′-CCSCRGGC-3′ (S = C or G; [208]) are similar. Alternatively, but not exclusively,
JCPyV LT sequesters AP-2 because SV40 LT was shown to interact with AP-2 and to prevent binding to
DNA [208]. JCPyV-mediated downregulation of BAG3, which would stimulate cell death. This may
seem unfavourable for the successful viral replication. However, another study by the same group
showed that the JCPyV LT and BAG3 associate interaction is important for autophagic degradation of
LT [209]. Hence, by downregulating BAG3, LT prevents its own degradation. Immunoprecipitation
studies showed the interaction between BAG2, BAG3, and BAG5 with MCPyV LT as well as sT, whereas
BKPyV sT bound BAG2, and BAG3. However, the biological consequences of these interactions were
not tested [122].
Expression of Bcl-2, which is an anti-apoptotic protein that promotes cell survival [210], was
significantly (p = 0.05) downregulated in MCPyV-positive non-small cell lung cancer samples compared
to virus-negative tumours and healthy adjacent tissue, while there were no significant differences
in mRNA levels of the pro-apoptotic Bax gene between the different specimens [116]. Few samples
were compared and the mechanism by which MCPyV may affect transcription of the Bcl-2 gene
was not investigated. However, in another study on a larger cohort of MCC patients (n = 116), no
statistically significant correlation was found between the presence of the Bcl-2 protein (levels not
quantitated) and MCPyV DNA in the tumour samples [211]. Transcriptome analysis of MCPyV-negative
and MCPyV–positive MCC tumours could not detect differences in Bax and Bcl-2 levels [212].
The examination of different tumour types may explain the discrepancy between these studies.
Another inhibitor of cell death is survivin, and its expression is upregulated in most cancers [213].
By comparing the transcript level in MCPyV-positive with MCPyV-negative MCC, Arora and co-workers
found that ~10% of the 11,500 genes examined were more than three-fold elevated in the virus-positive
tumours [212]. A seven-fold upregulation of survivin transcript levels was observed. LT, but not sT,
was shown to upregulate expression of survivin [212,214]. Accordingly, RNA interference-mediated
depletion of MCPyV early proteins resulted in reduced expression of survivin [172]. Survivin expression
is regulated by RB/E2F signaling. Both pRb and p130 can interact with the survivin promoter and
repress transcription, whereas E2F members can activate transcription [215]. This suggests that LT
induces survivin transcription by usurping pRb/p130, which impairs pRb/p130′s repressing activity
on E2F. A LT mutant unable to bind pRb did not stimulate survivin transcription [212]. MCPyV may,
thus, through LT-mediated upregulation of survivin, prevent apoptosis. The potent survivin inhibitor
YM155 inhibited growth of MCPyV-positive MCC cells in vitro and of xenografts in NOD-SCIDγmice.
Bortezomib, which is another survivin inhibitor, also inhibited MCC cell growth in vitro, but was not
active against the MCC xenografts in mice [212]. However, the role of survivin in MCPyV-induced
MCC may not be absolutely required because no correlation between survivin expression and MCPyV
positivity was found in 64 MCC samples [216]. JCPyV infection of oligodendrocytes and astrocytesic
cells also leads to a transiently increased expression of survivin. LT is a likely candidate to upregulate
expression of survivin because it was shown to bind and activate the surviving promoter [217].
3.11. Ubiquitination-Proteasomal Degradation Pathway
Ubiquitination involves the covalent attachment of a 76 amino acid peptide to target proteins.
This labels the proteins for proteolytic degradation by a multiprotein complex known as the 26 S
proteasome. The proteasome function is essential for protein homeostasis and influences the regulation
of most cellular processes, including cell survival, cell signaling, and cell cycle progression [218,219].
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Consequently, dysfunction of the proteasomal system is associated with numerous diseases, including
cancer [220,221]. The ubiquitination-proteasomal pathways plays an important role in virus life cycles.
It may protect the cell from viral infection by degrading viral proteins, but, on the other hand, viral
proteins can hijack this pathway to ensure viral replication and even virus-induced oncogenesis [222].
JCPyV LT binds β-transducin-repeat containing proteins 1 and 2 (βTrCP1 and βTrCP2), which are
F-box proteins that are part of the E3 ubiquitin ligase complex SCFFbw7 (Skp1, Cul1, and F box protein;
F box and WD repeat domain-containing 7) [223]. This interaction required the DSGHGSS (residues
639–645) motif of LT and phosphorylation of Ser-640 and to a lesser extend Ser-644. The LT: βTrCP
interaction did not affect the stability of LT, which suggests that LT is not a substrate, nor were the
levels of β-catenin, a βTrCP1 substrate, changed. The effect on other βTrCP1/2 substrates was not
investigated. LT of BKPyV (DSGHGSS), MCPyV (DSGTFSQ), and HPyV10 (DSGINSQ) also contain
a putative βTrCP1/2 binding motif, whereas TSPyV (DSGFQTQ) and LIPyV (DSGLFTQ) LT have a
putative motif, but lack the serine phosphoacceptor site. SV40 LT, which contains the motif DSGHETG,
did not interact with βTrCP1 [223]. This suggests that Thr cannot functionally replace Ser and that
the LT of BKPyV, MCPyV, and HPyV10, but not of TSPyV and LIPyV may interact with βTrCP. No
possible βTrCP binding motifs were detected in the LT of the other HPyV (our unpublished results).
The functional implications of the JCPyV LT: βTrCP association remains unexploited, but a JCPyV LT
S640A mutant (serine 640 replaced by alanine) impeded viral replication [223]. Moreover, interaction of
LT with βTrCP may perturb its involvement in cell cycle regulation and the proteasomal pathway [224],
which may lead to a transformation.
MCPyV sT was found to bind and inhibit the E3 ubiquitin ligase complex SCFFbw7. This
resulted in stabilization of MCPyV LT, which is a substrate for the E3 ligases SCFFbw7, β-TrCP,
and Skp2 [225]. sT-induced stabilization of LT stimulated viral replication and sT also prevented
proteasomal degradation of cellular SCFFbw7 targets such as the oncoproteins c-MYC and cyclin
E [226]. Furthermore, transformation of rodent fibroblasts in vitro, by sT, was SCFFbw7-dependent [226].
Moreover, MCPyV sT was also shown to interact with two other E3 ubiquitin ligases: Cdc20-anaphase
promoting complex [40] and β-TrCP [227], and by targeting E3 ubiquitin ligases, sT stimulated genome
instability [225]. All these findings imply that MCPyV sT-mediated inhibition of E3 ubiquitin ligases
may be an important contributor in MCPyV-induced tumorigenesis, whereas, during lytic infection, sT
may enhance viral replication by stabilizing LT. A recent study, however, failed to detect interaction
between sT and SCFFbw7 or β-TrCP, as well as between LT and SCFFbw7. Furthermore, sT was
demonstrated to stabilize LT independently of SCFFbw7 [228]. The authors did not observe increased
c-Myc levels when sT was expressed. The reason for these discrepancies is presently unknown.
MCPyV and BKPyV sT can form a complex with STIP1 homology and U-box containing protein 1
(STUB1), which is also known as carboxy terminus of Hsc70 interacting protein (CHIP) [122]. This
protein has E3 ubiquitin ligase activity and, hence, plays a role in ubiquitin-mediated degradation by
the proteasome [229]. This protein has a role in innate and adaptive immunity [230].
3.12. Immune Response Pathways
3.12.1. NFκB Signaling Pathway
NFκB is a family of transcription factors that consists of five members that can form homodimers
and heterodimers. NFκB is kept in an inactive state in the cytoplasm through interaction with members
of the inhibitor of κB (IκB) proteins. Activation of the canonical NFκB pathway is mediated by the
IκB kinase (IKK) complex, a heterotrimer of the protein kinases IKKα and IKKβ, and the regulatory
subunit IKKγ, which is also referred to as an NFκB essential modulator (NEMO). Activation of IKK
depends on phosphorylation of IKKα and IKKβ. The activated IKK complex will then phosphorylate
IκB, which results in its degradation. Hence, NFκB is released and translocates to the nucleus, where it
affects transcription of NFκB-responsive genes [231]. The transcriptional activity of NFκB is increased
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by phosphorylation [232]. NFκB target genes encode proteins involved in inflammation, but also the
antiviral response [233]. The implication of NFκB in immune responses is well-known [234].
Ectopically expressed MCPyV sT was found to inhibit the NFκB pathway and downregulate
expression of NFκB target genes such as CCL20, CXC-9, IL-8, and TANK in HEK293 and the
virus-negative MCC cell line MCC13 [49]. The authors found that sT inhibited phosphorylation
of IKKα and IKKβ, which prevents phosphorylation of IκB and reduces nuclear translocation of NFκB.
sT was shown to interact with NEMO and PP4C [49]. Although sT could bind PP4C, interaction with
PP4 regulatory subunit 1 (PP4R1) was required for an interaction with NEMO. Therefore, sT associated
with a PP4R1-PP4C complex, which mediated binding to NEMO [46]. Taken together, these results
suggest that sT stimulates the interaction between NEMO and the protein phosphatase PP4C-PP4R1
complex. Consequently, NEMO-mediated recruitment of PP4C to the IKK complex reduces IKK
phosphorylation, with subsequent inhibition of IκB and failure to release, activate (phosphorylate),
and translocate NFκB to the nucleus. Studies on MCC biopsies may jeopardize the inhibitory role
of sT on NFκB because significantly higher (p = 0.034) expression of pSer-536 RelA/p65 subunit of
NFκB was observed in MCPyV-positive (n = 24) compared to virus-negative (n = 17) MCCs. This
phosphorylated form resided exclusively in the nucleus [235]. Neither BKPyV sT nor JCPyV sT
interacted with PP4R1 [46], which suggested that this unique property of MCPyV sT may contribute to
the oncogenic properties of this virus.
The DDR can activate the NFκB pathway also referred to as the “inside-out” or “nuclear to
cytoplasm” NFκB signaling [236]. This nuclear initiated NFκB activation occurs via ATM, which
phosphorylates NEMO. Upon phosphorylation, NEMO is ubiquitinated and the ATM: NEMO complex
is exported to the cytoplasm and NEMO will bind to and activate IKK. IKK, in turn, phosphorylates
IκBα, which triggers degradation of IκBα and, as a result, activation of NFκB [236]. White and
co-workers showed that JCPyV infection of the human glial cell line SVG-A provoked nuclear transfer
of NEMO and that LT caused modification of NEMO [135]. NEMO translocation was most prevalent
three days after infection, while, at five days, p.i. most NEMO was relocated to the cytoplasm. At three
days p.i., however, little or no phosphorylated ATM was detected in JCPyV-infected cells. Because
inhibition of ATM suppressed viral replication, the authors speculated that stress induced upon JCPyV
infection activates ATM, which, in a NEMO-dependent manner, activates NFκB. This transcription
factor has previously been shown to stimulate transcription of the early and late viral genes and viral
DNA replication [237].
Bromodomain protein 4 (Brd4) is a member of the bromodomain and extra terminal domain
family of proteins that recognized acetylated lysine. It acts as a transcriptional and epigenetic regulator
by activating transcription factors, transcription elongation factor p-TEFb, and chromatin remodeling
proteins. Moreover, it can interfere with the NFκB pathway by interacting with IκB [238,239]. Its role
in cancer and inflammation is well-established [240–242]. Brd4 was found to interact with MCPyV
LT, which is bound to the replication origin of the viral DNA. Brd4, in turn, helps recruit replication
factor C by direct binding to the largest subunit 1 (RFC1), which facilitates replication of the viral
genome [243]. It is not known whether LT of other human polyomaviruses interact with Brd4, but Brd4
stimulates JCPyV early transcription in an NFκB-dependent manner [244].
3.12.2. Innate Immune System
The innate immune system forms an important defense against viruses. Specific pattern
recognition receptors (PRRs) serve to identify pathogen-associated molecular patterns (PAMPs)
and danger-associated molecular patterns (DAMPs) [245,246]. One of the best understood families
of PRRs are the toll-like receptors (TLR), which consists of 10 members recognizing specific PAMPs.
TLR2 and TLR4 recognize glycoproteins of the virus particle. TLR3, TLR7, and TLR8 detect viral RNA,
and TLR9 is a sensor for hypomethylated dsDNA. Binding of viral dsDNA to TLR9 will activate the
NFκB signaling pathway and result in the production of inflammatory mediators [246]. The early
regions of BKPyV, JCPyV, KIPyV, WUPyV, and MCPyV downregulated the expression of TRL9 in the B
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lymphocyte RPMI-8226 cell line [247]. The effect seemed to be cell-specific because the early region
of KIPyV and WUPyV had no effect on TLR9 expression in naturally immortalized keratinocytes.
For MCPyV, it was shown that LT is responsible for inhibiting TLR9 expression by targeting the
transcription factor C/EBPβ. sT could also reduce TLR9 expression to a lesser extent. The C/EBPβ
levels did not closely reflect the downregulation of TRL9 by the other HPyV, which suggests that
they may use different mechanisms. The mechanism by which sT downregulates TLR9 expression
is not known, but it may operate by stabilizing LT [226]. Immunohistochemical staining of MCC
biopsies confirmed that decreased expression of TLR9 correlated strongly with MCPyV positivity [248].
The exact role of HPyV-mediated downregulation of TLR9 remains unknown, but it may facilitate
establishing a viral infection and/or may help virus-positive tumours to evade the immune system.
3.12.3. Interferon Signaling Pathway
Infection of primary human foetal glial cells and U87MG glioblastoma cells with JCPyV induced
the expression of interferon-(IFN) stimulated genes [100]. Another study showed that the LT truncated
variant of BKPyV and JCPyV LT, but not their sT, could upregulate the expression of IFN-stimulated
genes in mouse embryonic fibroblasts. This induction caused an antiviral state and required signal
transducer and activator of transcription 1 (STAT1) activation by LT with an intact RB binding
domain [249]. The mechanism by which LT induces phosphorylation/activation of STAT1 via the
RB binding motif remains unsolved. BKPyV and JCPyV infection triggers expression of interferon
inducible genes in a cell-specific and virus-specific manner. JCPyV infection of primary human
astrocytes had no effect on the expression of interferon stimulated genes [250], whereas infection of
RPTE cells induced the expression of IFN-stimulated genes [251]. On the other hand, BKPyV infection
of RPTE cells failed to induce expression of IFN-stimulated genes [251,252]. Another study found that
BKPyV enhanced the expression of the IFN-stimulated genes ISG15 and IFIT3 in human endothelial
cells [253]. BKPyV infection of microvascular endothelial cells activated the IFN signaling pathway
and induced expression of IFN-stimulated genes [252]. The transcription factors interferon regulatory
factor 3 (IRF3) and STAT1 were activated upon BKPyV infection of microvascular endothelial cells,
but not in RPTE cells [252]. A recent proteomic-based study could not detect changes in protein levels
of IFN-stimulated genes in BKPyV-infected RPTE cells after 24, 48, and 72 hours p.i. [195]. It is unclear
why some cells trigger expression of IFN-stimulating genes in response to BKPyV or JCPyV infection
and others do not, but the induced antiviral state may restrict BKPyV or JCPyV replication in the host
and enable the establishment of a long-term infection [100]. Alternatively, cells may lack the machinery
to detect viral infection or viruses may counteract cellular defense responses through immune-evasion
activity. Hence, no expression of IFN-stimulating genes occurs after HPyV infection [195,252].
3.12.4. Cytokines/Chemokines
The primary function of cytokines, including chemokines, is the induction of inflammation
and immune responses during viral infection [254–257]. Infection of cell cultures with JCPyV or
BKPyV led to the upregulation of cytokines. For example, infection of human embryonic neural
progenitor cells with JCPyV resulted in significant upregulation of the cytokines/chemokines such
as CCL5/RANTES, GRO, CXCL1/GROα, CXCL16, CXCL8/IL-8, CXCL5/ENA78, and CXCL10/IP-10
and the chemokine receptor CXCR2. Infection of human cortical collecting duct epithelial cells with
BKPyV resulted in downregulation of TNFα expression, but upregulation of the TNF receptors 1
and 2, TLR3, RIG-1, IL-6, IL-8/CXC8, CCL5/RANTES, CCL2/MCP-1, and CXCL10/IP-10 [258–260].
The mechanism(s) by which BKPyV and JCPyV alter the expression of these proteins has not been
investigated, but BKPyV LT expression coincided with upregulation of these proteins so that a role for
LT cannot be excluded [258,259]. Comparing the expression levels of 85 cytokines in non-infected and
in BKPyV infected human kidney epithelial cells did not reveal any significant changes, even over
time [136]. MCPyV can also modulate the expression of cytokines. Transcriptomic analysis of BJ human
foreskin fibroblasts stably expresses a C-terminally truncated variant of MCPyV LT (residues 1–339)
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or this truncated LT plus sT resulted in increased expression of several cytokines and chemokines,
including IL-1β, IL-6, IL-8, and CXCL1 [261]. Another chemokine whose expression is upregulated
by MCPyV is chemokine (C-C motif) ligand 17/thymus and activation-regulated (CCL17/TARC).
Full-length and truncated MCPyV LT, but not sT, enhanced the CCL17/TARC promoter activity and
increased protein levels [262]. The presence of a putative E2F binding site in the CCL17/TARC
promoter suggests that LT (partially) triggers CCL17/TARC expression through the activation of E2F
by relieving repression by RB. The chemokine-like proteins prokineticins possess angiogenic and
immunoregulatory activities and may, therefore, be implicated in cancer [263]. MCPyV-positive MCCs
had higher prokineticin-2 transcript levels than the virus-negative tumours [264]. The mechanism by
which MCPyV may affect prokineticin-2 expression has not been scrutinized, nor has the role in the life
cycle or involvement in MCC been explored.
3.13. Nuclear Receptor Signaling Pathway
Nuclear receptors are a diverse family of intracellular receptors that also act as transcription
factors. Their ligands can pass the plasma membrane and include steroid hormones, thyroid hormone,
vitamin D3, retinoic acid, and fatty acid metabolites. Ligand binding, posttranslational modifications,
and recruitment of co-activators result in activation of nuclear receptors. They bind as monomers,
homodimers, or heterodimers to specific DNA sequences, which directs transcription of their target
genes. Nuclear receptors regulate cellular processes such as cell proliferation, development, metabolism,
inflammation, tissue homeostasis, apoptosis, and reproduction [265,266]. The implication of nuclear
receptors in cancer is well-known as perturbed nuclear receptor signaling, which leads to aberrant gene
expression. Nuclear receptors also play a role in regulating angiogenesis and inflammation [267–269].
Co-expression of BKPyV LT and sT stimulated oestrogen receptor-mediated transcription.
However, when expressed separately, only LT induced oestrogen receptor-mediated transcription [270].
The mechanism by which LT/sT regulated the transcriptional activity of the oestrogen receptor has
not be determined, but did not require interaction between LT and the receptor. Glucocorticoids,
progesterone, and oestrogen stimulated the BKPyV promoter, enhanced viral early and late gene
expression, and increased the virus yield [271]. Whether LT stimulates transcription directed by the
glucocorticoid and progesterone receptors has not been investigated, nor has the effect of other HPyV
on nuclear receptor signaling been examined.
3.14. Phospholipid Signaling Pathways
Sphingolipids are bioactive (phospho)lipids that act as important regulators of cellular processes
such as proliferation, cell survival, differentiation, migration, autophagy, and immune responses [272].
These molecules can affect signaling pathways, including PKCζ, NFκB, PI3K/AKT, and JNK and
dysregulation of sphingolipid metabolism contributes to tumorigenesis and metastasis [272–274].
Sphingosine kinases 1 and 2 (SK1 and SK2) are important metabolic enzymes in the formation of
sphingosine-1-phosphate [272], and expression levels of these protein kinases are frequently elevated
in many cancers [274]. Bhat and co-workers reported that the transcript levels of SK1 and SK2
were significantly higher in MCPyV-positive MCC cell lines compared to MCPyV-negative cells and
that ectopic expression of truncated variants of LT or of sT in human lung fibroblasts MRC-5 cells
resulted in increased SK1 and SK2 mRNA concentrations [275]. The activation levels of SK1/2 were
not investigated, nor is the mechanism by which LT and sT upregulate SK1/2 transcript levels known.
Because truncated LT variants lacking their DNA binding domain still increased SK1/2 mRNA levels,
direct binding of LT to the promoters of the SPHK1 and SPHK2 genes can be excluded. SK1 becomes
activated by Ser-225 phosphorylation and this site is dephosphorylated by PP2A [272]. Therefore,
MCPyV sT may prolong SK1 activation by inhibiting PP2A-mediated dephosphorylation. Inhibition of
SK1 and SK2 attenuated MCC tumour growth [275], so it may seem that MCPyV LT and sT upregulate
expression of SK1 and SK2 to promote proliferation of the tumour cells.
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3.15. Metabolic Pathways
Viruses can alter the host metabolism for their own benefit to promote optimal viral replication
conditions [276]. Human tumour viruses have also been shown to alter glucose metabolism in the
tumour cell, which is one of the hallmarks of cancer [163,277]. Studies with JCPyV have shown the
importance of normal glucose metabolism for efficient replication. Glucose starvation of human
glioblastoma U-87MG cells transiently expressing JCPyV LT and mouse medulloblastoma BsB8 cells
stably expressing JCPyV LT and sT, reduced LT protein levels in the glioblastoma cells and both LT
and sT levels in the medulloblastoma cells. Activation of 5′-adenosine monophosphate activated
protein kinase (AMPK) caused repression of LT expression, whereas inhibition of AMPK restored LT
protein levels under glucose deprivation in both cell types. On the other hand, JCPyV LT was shown to
suppress 5′-adenosine monophosphate activated protein kinase (AMPK) and to upregulate expression
of the glycolytic enzyme transaldolase-1 during glucose deprivation [278]. The interplay between
AMPK and LT enabled JCPyV to maintain the cells in the G2 phase during glucose deprivation, which,
thereby, prevents the cells from dying. A similar function was found for SV40 sT, which activated
AMPK in a PP2A-dependent manner under conditions of glucose starvation and this reduced the rate
of cell death [279]. The mechanism by which JCPyV LT regulates AMPK and whether JCPyV sT can
activate AMPK remains to be resolved. Doxocyclin-induced expression of MCPyV sT in human lung
fibroblast IMR90 cells stimulated transcript levels of glycolytic genes, including hexokinase 2, glucose
transporters GLUT1 and GLUT3, transporter for lactate and pyruvate SLC16A1 (MCT1), and the
transcription factors MLX and MLXIP, which regulate the transcription of genes encoding glycolytic
enzymes [66]. sT-induced expression of SLC16A1 (MCT1) is partially mediated by NFκB [66], but other
pathways are likely involved in sT-induced upregulation of metabolic genes. MCPyV-mediated
upregulation of glycolysis may contribute to the oncogenic potential of this virus.
4. Conclusions and Future Research Directions
Most human polyomaviruses establish a life-long persistent, but harmless infection in healthy
people. However, they may cause diseases in immunocompromised individuals. Only one HPyV
and MCPyV is recognized as a human oncovirus, whereas BKPyV and JCPyV are possibly oncogenic
viruses [280]. Currently, no specific vaccines or efficient drugs against these viruses exist [2]. Human
polyomaviruses, like other viruses, reprogram the intracellular environment of their host cell to create
an optimal environment for their replication or, in some cases, to transform the host cell into a tumour
cell. One mechanism by which viruses interfere with cellular processes is by targeting signaling
pathways. The LT and sT of HPyV are multifunctional proteins that are not only required for virus
replication, but they are also pivotal in modulating multiple cellular signaling pathways, which we
described in this review and summarized in Figure 2A,B. Through their association with components
of signaling pathways, HPyV can affect cellular processes such as cell cycle, cell survival, DNA
damage repair, transcription, and translation and evade immune surveillance. All these processes will
support viral replication. However, these functions of LT and sT may also contribute to oncogenesis,
as outlined in this review. The mechanisms by which these viral proteins interfere with different signal
transduction pathways and the biological implications are not fully understood. As outlined above,
HPyV encode LT and sT with the potential to modulate different signaling pathways that are known
to be involved in cancer when they are perturbed. However, only MCPyV is firmly associated with
cancer, while a probable implication of BKPyV and JCPyV in human tumours is suggested [27,28,281].
The reason for the differential oncogenic potential of HPyV is not fully understood. In vitro studies
and transgenic animal models have shown that MCPyV sT is more oncogenic than LT, while the
opposite is true for BKPyV and JCPyV, whose LT seems to be more oncogenic than sT [282]. BKPyV
and JCPyV LT share 83% amino acid identity, whereas BKPyV LT (resp. JCPyV LT) and MCPyV LT
are only 49% (resp. 48%) identical. Similarly, the sT of BKPyV and JCPyV are 78% identical, whereas
BKPyV sT (resp. JCPyV sT) and MCPyV sT share 35% (resp. 33%) identity. These differences in LT and
sT sequence may explain why these proteins bind different cellular targets (Table 1) and, hence, have
Int. J. Mol. Sci. 2019, 20, 3914 20 of 34
different oncogenic properties. Moreover, the affinity for the cellular proteins can be different, as was
illustrated for, e.g., PP2A (Section 2.2) and the retinoblastoma family members (Section 3.8). Other
factors that may explain the distinct oncogenic properties of HPyV is the cell tropism, state of the viral
genome (integrated or episomal), expression levels of LT and sT, and variants of LT (e.g., truncated
MCPyV LT in MCC). This is an important area that needs further investigation. More research is also
required to understand the exact molecular basis for the effect of LT and sT on signaling pathways.
Comparative proteomic studies between control cells and LT or/and sT expressing cells can identify
signaling proteins whose expression is affected by these viral proteins. Similarly, phospho-proteomics
of HPyV sT expressing and control cells can be performed to identify putative targets of protein
phosphatases that are modulated by HPyV sT and proteomic studies. The biological consequence of
LT/sT interaction partners needs to be further explored and phospho-specific antibodies can be used to
identify protein kinases and their substrates that become activated upon expression of LT and/or sT.
This additional knowledge can then be used to develop therapeutic drugs that prevent LT and sT to
perturb signaling pathways. The intimate co-existence between the virus and its host and the necessity
of these signaling pathways for normal cellular function forms a big challenge in designing drugs that
affect the virus but not the host.
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PTCH Patched
Rb Retinoblastoma
RFC Replication factor C
RPTE Primary human renal proximal tubule epithelial
SHH Sonic hedgehog
SK Spingosine kinase
Smo Smoothened
sT Small t-antigen
STAT Signal transducer and activator of transcription
STUB1 STIP1 homology and U-box containing protein
TCF T-cell factor
TEFb Transcription elongation factor b
TLR Toll-like receptor
TNFα Tumour necrosis factor α
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